Health
‘Another agent in our arsenal’: Finerenone benefits extend to those with, without CVD – Healio
Among adults with chronic kidney disease and type 2 diabetes, the mineralocorticoid receptor inhibitor antagonist finerenone reduced the incidence of CV events…
Source/Disclosures
Source: Filippatos G, et al. LBS.07: Randomized trials — brain, kidney and heart. Presented at: American Heart Association Scientific Sessions; Nov. 13-17, 2020 (virtual meeting).
Disclosures:
Filippatos reports he receives lecture or advisory board fees from Amgen, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Servier and Vifor. Wanner reports he receives lecture or advisory fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, FMC, Gilead, GlaxoSmithKline and…
-
General19 hours agoWhy the nation needs the Nationals to ditch Net Zero
-
General19 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News23 hours agoBrisbane rising on global rankings, but still behind southern capitals
-
General19 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire